

KINASE INHIBITORS

The CNIO has developed novel pharmaceutical compounds, which are useful as inhibitors of protein or lipid kinases, such as inhibitors of the phosphoinositide 3OH kinase (PI3 kinase) family, particularly the PI3K class I sub-type, or, inhibitors of the mammalian target of rapamycin (mTOR).

Industrial partners are being sought to collaborate through a patent license agreement for the development and exploitation of the technology.


Description

The inventors have found a novel set of compounds useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

Main innovations and advantages

Compounds of the invention are effective inhibitors of protein or lipid kinases, e.g. PI3K, such as class I PI3K, and/or mTOR.

The invention also relates to the use of such compounds as medicaments, to the use of such compounds for the treatment of a disease in which the inhibition of such protein or lipid kinases is desired and/or required such as cancer, to pharmaceutical compositions containing them, and to synthetic routes for their production.



Intellectual property

Patent title :

“Imidazopyrazines for use as kinase inhibitors”

Applicant: Spanish National Cancer Research Center (CNIO)

International patent application:

WO2010119264 (A1)

Patent granted in:

Australia, Brazil, Canada, China, Europe, Eurasia, India, Israel, Japan, South Korea, Mexico, Philippines, USA and South Africa

For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3
28029 Madrid Spain
technologytransfer@cnio.es
www.cnio.es
@CNIO_Cancer